O&M offered $13.80 per share in cash for Medical action, representing a 93% premium over the stock’s average closing price over the last year. The news sent MDCI shares soaring from a close last night at $7.07 to a new 52-week high of $13.73 today.
OMI shares saw a much more modest boost, gaining 1.4% to trade at $35.33 as of about 3:10 p.m. EST today.
O&M said the acquisition will play an integral role in a strategy the company calls "Connecting the World of Medical Products to the Point of Care."
"The acquisition of Medical Action is consistent with our strategic focus and a natural extension of Owens & Minor’s core capabilities as we look to broaden our service offering," O&M chairman & CEO Craig Smith said in prepared remarks. "It meets the needs of both our provider and manufacturer customers by providing them a more complete and cost-effective solution for the delivery of procedure-specific product kits."
Medical Action posted nearly $288 million in net sales from continuing operations last fiscal year, nearly half of which was comprised of sales to O&M, according to a press release. O&M expects the acquisition to add to its non-GAAP net income starting in fiscal 2015.
The boards of both companies have already approved the transaction, which O&M plans to pay for with existing cash on hand and borrowings under its credit facility, the company said.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.